RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use (2019)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 62/680,845, filed Jun 5, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,338,455 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | ||
| US 11,926,843 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | LifeEDIT Therapeutics, Inc. | In force | High confidence | ||
| US 11,162,114 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Lifeedit Therapeutics, Inc. | In force | High confidence | ||
| Application 19/216,399 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use Pending Not granted | Life Edit Therapeutics, Inc. | Pending | Not granted | not computed |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Lifeedit, Inc..
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.